Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA V: FDA Could Offer Non-Binding Advice, If It’s Binding

Executive Summary

FDA is interested in giving non-binding advice to drug sponsors under PDUFA V, as long as it is binding, officials told industry.
Advertisement

Related Content

Tropical Disease Development Partnerships Want More Help From U.S. FDA
Tropical Disease Development Partnerships Want More Help From FDA
FDA Could Answer "Clarifying" Questions, But Only For Firms Without Approved Product
FDA Could Answer "Clarifying" Questions, But Only For Firms Without Approved Product
PhRMA's Policy Pitch: Protect Industry Innovation Or We Go The Way Of Auto Makers
PDUFA Talks: FDA Floats “Information Sharing” Pause In New Review Model
PDUFA Update: FDA Wants To Automatically Extend Complex Application Reviews
PDUFA Update: FDA Wants To Automatically Extend Complex Application Reviews

Topics

Advertisement
UsernamePublicRestriction

Register

PS053042

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel